Differences in functional roles between activated platelets and platelet-derived microparticles.

Differences in functional roles between activated platelets and platelet-derived microparticles. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Differences in functional roles between activated platelets and platelet-derived microparticles. Abstract Text:

Shosaku Nomura,Norihito Inami,Toshiji Iwasaka,Shosaku Nomura,Norihito Inami,Toshiji Iwasaka,

Differences in functional roles between activated platelets and platelet-derived microparticles. Publishing Authors By Initials

S Nomura,N Inami,T Iwasaka,S Nomura,N Inami,T Iwasaka,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Differences in functional roles between activated platelets and platelet-derived microparticles. Journal Published:

PUBLICATION TYPE: Letter

Journal: Thrombosis and haemostasis

VOLUME: 98

Page Numbers: 1143-4

Journal Abbreviation: Thromb. Haemost.

ISSN: 0340-6245

DAY: 16

MONTH: Nov

YEAR: 2007

Differences in functional roles between activated platelets and platelet-derived microparticles. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7608063

Differences in functional roles between activated platelets and platelet-derived microparticles. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Differences in functional roles between activated platelets and platelet-derived microparticles. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Differences in functional roles between activated platelets and platelet-derived microparticles.

AFFILIATION:

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Thromb Haemost

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Differences in functional roles between activated platelets and platelet-derived microparticles Related Publications

• Adiponectin incompletely prevent MCP-1-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease.
• Angiotensin II type 1 receptor blocker preserves tolerance to ischemia-reperfusion injury in Dahl salt-sensitive rat heart.
• Antiproliferative effects of the major tea polyphenol, (-)-epigallocatechin gallate and retinoic acid in cervical adenocarcinoma.
• Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus.
• Differences in functional roles between activated platelets and platelet-derived microparticles.
• Effects of pitavastatin on adiponectin in patients with hyperlipidemia.
• Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment.
• Limitation of antiplatelet therapy after percutaneous coronary intervention.
• Management of patients with recurrent nephrosis and intractable edema by intraperitoneal instillation of icodextrin solution.
• N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster.
• Nicorandil suppressed myocardial injury after percutaneous coronary intervention.
• Non-invasive detection of ischemic left ventricular dysfunction using rest gated SPECT: expectation of simultaneous evaluation of both myocardial perfusion and wall motion abnormality.
• Prognosis of subjects with brugada-type electrocardiogram in a population of middle-aged Japanese diagnosed during a health examination.
• Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
• Three-dimensional echocardiographic assessment of left ventricular function in takotsubo cardiomyopathy.
• Uterine artery embolization followed by dilation and curettage for cervical pregnancy.